Helix Free Cash Flow Yield vs Capex To Depreciation Analysis
| HBP Stock | CAD 0.77 0.07 10.00% |
Helix BioPharma financial indicator trend analysis is much more than just examining Helix BioPharma Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Helix BioPharma Corp is a good investment. Please check the relationship between Helix BioPharma Free Cash Flow Yield and its Capex To Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Free Cash Flow Yield vs Capex To Depreciation
Free Cash Flow Yield vs Capex To Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Helix BioPharma Corp Free Cash Flow Yield account and Capex To Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Helix BioPharma's Free Cash Flow Yield and Capex To Depreciation is -0.12. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Helix BioPharma Corp, assuming nothing else is changed. The correlation between historical values of Helix BioPharma's Free Cash Flow Yield and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Helix BioPharma Corp are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Free Cash Flow Yield i.e., Helix BioPharma's Free Cash Flow Yield and Capex To Depreciation go up and down completely randomly.
Correlation Coefficient | -0.12 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most indicators from Helix BioPharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Helix BioPharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Helix BioPharma's Discontinued Operations is very stable compared to the past year. As of the 23rd of November 2024, Sales General And Administrative To Revenue is likely to grow to 1.36, while Selling General Administrative is likely to drop about 2.8 M.
| 2023 | 2024 (projected) | Minority Interest | 117K | 111.2K | Reconciled Depreciation | 14K | 13.3K |
Helix BioPharma fundamental ratios Correlations
Click cells to compare fundamentals
Helix BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Helix BioPharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.9M | 4.1M | 3.7M | 1.0M | 1.5M | 1.4M | |
| Other Current Liab | 49K | 380K | (1K) | 1.4M | 1.2M | 1.3M | |
| Total Current Liabilities | 1.9M | 3.9M | 3.4M | 1.9M | 1.6M | 2.2M | |
| Total Stockholder Equity | 2.4M | (1.4M) | 319K | (844K) | (90K) | (85.5K) | |
| Property Plant And Equipment Net | 246K | 47K | 35K | 33K | 29.7K | 28.2K | |
| Net Debt | (4.1M) | 47K | (784K) | (808K) | (929.2K) | (975.7K) | |
| Retained Earnings | (180.5M) | (188.6M) | (195.1M) | (201.4M) | (210.7M) | (221.2M) | |
| Accounts Payable | 1.4M | 1.5M | 599K | 493K | 855K | 1.1M | |
| Cash | 4.2M | 3.6M | 3.3M | 808K | 1.1M | 1.0M | |
| Non Current Assets Total | 246K | 47K | 35K | 33K | 29.7K | 28.2K | |
| Cash And Short Term Investments | 4.2M | 3.6M | 3.3M | 808K | 727.2K | 690.8K | |
| Net Receivables | 180K | 353K | 280K | 62K | 55.8K | 53.0K | |
| Common Stock Shares Outstanding | 127.7M | 137.9M | 149.5M | 193.2M | 49.0M | 96.5M | |
| Liabilities And Stockholders Equity | 4.9M | 4.1M | 3.7M | 1.0M | 926.1K | 879.8K | |
| Other Current Assets | 245K | 100K | (1K) | 126K | 113.4K | 179.3K | |
| Other Stockholder Equity | 25.5M | 27.9M | 37.6M | 44.1M | 39.7M | 44.3M | |
| Total Liab | 1.9M | 5.5M | 3.4M | 1.9M | 1.6M | 2.4M | |
| Property Plant And Equipment Gross | 246K | 1.8M | 1.8M | 1.8M | 1.8M | 1.9M | |
| Total Current Assets | 4.7M | 4.0M | 3.7M | 996K | 1.5M | 1.4M | |
| Accumulated Other Comprehensive Income | 20.1M | 19.6M | 10.3M | 4.4M | 5.0M | 2.8M | |
| Net Tangible Assets | (3.3M) | 2.4M | (1.4M) | 319K | 287.1K | 272.7K | |
| Property Plant Equipment | 246K | 47K | 36K | 33K | 29.7K | 28.2K | |
| Non Currrent Assets Other | (3.0) | (1.0) | 0.0 | 1K | 900.0 | 855.0 | |
| Common Stock | 137.3M | 139.7M | 147.5M | 152.1M | 174.9M | 127.4M | |
| Capital Surpluse | 25.5M | 27.9M | 37.6M | 44.1M | 50.8M | 29.9M | |
| Current Deferred Revenue | 38K | 124K | 301K | 345K | 396.8K | 416.6K | |
| Net Invested Capital | 2.4M | 2.2M | 2.8M | (844K) | (90K) | (85.5K) | |
| Net Working Capital | 2.7M | 144K | 284K | (878K) | (123K) | (129.2K) | |
| Capital Stock | 137.3M | 139.7M | 147.5M | 152.1M | 158.6M | 155.6M |
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.82 | GOOG | Alphabet CDR | PairCorr |
| 0.81 | TSLA | Tesla Inc CDR | PairCorr |
| 0.79 | NVDA | NVIDIA CDR | PairCorr |
| 0.78 | AMZN | Amazon CDR | PairCorr |
| 0.75 | WMT | Walmart Inc CDR | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Balance Sheet is a snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Helix BioPharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Helix BioPharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Helix currently owns. An asset can also be divided into two categories, current and non-current.